Digital Biomarkers for Substance Use Detection

Abstract

Digital biomarkers have emerged as promising tools for the detection and monitoring of substance use disorders (SUDs), leveraging data from digital devices to provide objective, real-time measures of behavioral and physiological changes. This article critically reviews the current evidence and clinical applications of digital biomarkers in SUDs, exploring their epidemiological significance, underlying mechanisms, diagnostic utility, and integration into modern healthcare. We discuss current guidelines, recent advances, risk factors, and the future landscape of digital biomarker use for substance detection, aiming to inform clinicians and healthcare professionals about the practical and scientific implications of this rapidly evolving field.

Introduction

Substance use disorders (SUDs) remain a significant public health concern globally, with challenges in early detection, monitoring, and relapse prevention. Traditional methods for identifying substance use rely on self-reports, interviews, and laboratory-based toxicology, each with inherent limitations such as recall bias and infrequent sampling. Digital biomarkers objective, quantifiable physiological and behavioral data collected via digital devices offer a novel approach to continuous, real-time substance use monitoring. This review aims to provide an evidence-based overview of digital biomarkers in SUDs, focusing on their clinical utility, mechanisms, and guideline-driven applications for healthcare professionals.

Epidemiology / Disease Burden

Globally, the World Health Organization estimates that over 35 million people suffer from drug use disorders, with millions more affected by alcohol use disorders. Despite significant healthcare expenditure, many cases remain undetected or undertreated due to limitations in current screening methods. The high relapse rate in SUDs underscores the need for improved monitoring tools. Digital biomarkers have the potential to bridge gaps in epidemiological surveillance by providing scalable, population-level data on substance use patterns, risk stratification, and treatment response, especially in underserved and high-risk populations.

Pathophysiology

The pathophysiology of SUDs involves complex neurobiological processes, including alterations in reward, stress, and executive function circuits. Substance use impacts heart rate variability, electrodermal activity, sleep architecture, and movement patterns physiological domains measurable by digital sensors and smartphones. Digital biomarkers capture these subtle changes, enabling early detection of substance use events or relapse risk by identifying physiological and behavioral deviations from baseline. Mechanistically, this approach aligns with precision medicine by targeting individual-level changes associated with substance use behaviors.

Risk Factors

Risk factors for SUDs are multifactorial and include genetic predisposition, psychiatric comorbidities, environmental exposures, and social determinants. Digital biomarkers can augment risk assessment by integrating data on sleep disruption, geolocation patterns (e.g., visits to high-risk environments), communication changes, and stress-related physiological markers. These data streams facilitate personalized risk profiling and real-time intervention opportunities, particularly in patients with known vulnerabilities.

Clinical Features

Clinically, SUDs manifest as impaired control over substance use, craving, tolerance, withdrawal, and negative impacts on social or occupational functioning. Digital biomarkers can detect prodromal features such as sleep irregularities, altered speech patterns, or increased physiological arousal prior to overt substance use behaviors. Wearable sensors and smartphone apps can passively track these features, providing clinicians with actionable insights that complement patient history and physical examination findings.

Diagnosis

Diagnosis of SUDs traditionally relies on DSM-5 or ICD-10 criteria, supported by laboratory tests. Digital biomarkers offer an adjunctive diagnostic framework by providing continuous, objective evidence of substance use or related physiological changes. Devices can detect alcohol via transdermal sensors, monitor cardiac rhythm changes with wearables, or analyze behavioral cues through smartphone interaction data. Early validation studies show good sensitivity and specificity for certain digital biomarkers, although standardized protocols and regulatory approval remain ongoing challenges.

Treatment & Management

Digital biomarkers have transformative potential in SUD management by enabling just-in-time adaptive interventions (JITAIs), facilitating remote monitoring, and enhancing patient engagement. Real-time feedback from digital devices can alert patients and care teams to increased relapse risk, prompting timely support or medication adjustments. Integration with telehealth platforms and electronic health records further enhances coordinated care. However, ethical considerations regarding data privacy, consent, and digital literacy must be addressed to maximize patient benefit and minimize harm.

Recent Advances / Emerging Therapies

Recent advances include the development of machine learning algorithms that analyze multimodal digital biomarker data for predictive modeling of relapse or treatment response. Pilot studies utilizing passive smartphone sensing, wearable transdermal alcohol monitors, and voice analysis apps have demonstrated feasibility and clinical value. Emerging therapies integrate digital biomarkers with cognitive-behavioral interventions and contingency management, creating personalized, data-driven treatment pathways. Regulatory bodies are increasingly recognizing digital biomarkers in clinical research, with several ongoing trials assessing their efficacy and safety.

Guideline Recommendations

Current guidelines from organizations such as the American Society of Addiction Medicine (ASAM) and National Institute on Drug Abuse (NIDA) acknowledge the potential of digital health technologies, including digital biomarkers, for SUD care. Recommendations emphasize the need for rigorous validation, patient-centered design, data security, and integration with existing clinical workflows. Clinicians are encouraged to consider digital biomarkers as adjuncts to standard care, particularly in high-risk or remote populations, while maintaining adherence to established diagnostic and therapeutic protocols.

Conclusion

Digital biomarkers represent a paradigm shift in the detection and management of substance use disorders, offering objective, real-time insights that enhance traditional clinical approaches. While challenges remain in standardization, validation, and ethical use, ongoing research and guideline development are paving the way for their broader clinical adoption. Healthcare professionals should remain informed about the evolving landscape of digital biomarkers, integrating them judiciously into patient care to improve outcomes in substance use detection and intervention.